This review addresses the plausibility of hydrogen sulfide (H2S) therapy for acute lung injury (ALI) and circulatory shock, by contrasting the promising preclinical results to the present clinical reality. The review discusses how the narrow therapeutic window and width, and potentially toxic effects, the route, dosing, and timing of administration all have to be balanced out very carefully. The development of standardized methods to determine in vitro and in vivo H2S concentrations, and the pharmacokinetics and pharmacodynamics of H2S-releasing compounds is a necessity to facilitate the safety of H2S-based therapies. We suggest the potential of exploiting already clinically approved compounds, which are known or unknown H2S donors, as a surrogate strategy.

中文翻译：

---

急性肺损伤中的 H2S：治疗死胡同（？）

本综述通过将有希望的临床前结果与目前的临床现实进行对比，探讨了硫化氢 (H2S) 治疗急性肺损伤 (ALI) 和循环性休克的可行性。该综述讨论了如何非常谨慎地平衡狭窄的治疗窗口和宽度以及潜在的毒性作用、途径、剂量和给药时间。开发确定体外和体内 H2S 浓度的标准化方法，以及释放 H2S 的化合物的药代动力学和药效学，对于促进 H2S 疗法的安全性是必要的。我们建议利用已经临床批准的化合物（已知或未知的 H2S 供体）作为替代策略的潜力。